Sandoz Launches First MS Biosimilar TYRUKO® in US

Sandoz Group AG has introduced TYRUKO® (natalizumab-sztn) in the United States, marking the first and only FDA-approved biosimilar for multiple sclerosis (MS). Developed by Polpharma Biologics, this product offers a cost-effective option for patients with relapsing forms of MS. TYRUKO® is approved for all indications of Tysabri® and is expected to drive growth for Sandoz.

The TYRUKO® launch signifies a potential breakthrough in MS treatment affordability and accessibility. It is available through a REMS program due to risks like progressive multifocal leukoencephalopathy (PML). Sandoz partners with Labcorp for a JCV Antibodies testing program to support safe usage.

In addition to the US, TYRUKO® is available in 14 European countries. This launch is a strategic step toward Sandoz's leadership in the US biosimilars market, with initiatives to strengthen its neurology segment.